In this review:
Carfilzomib plus lenalidomide or cyclophosphamide in newly diagnosed MM
Ibrutinib lead-in followed by venetoclax in CLL
Carfilzomib dosing in relapsed/refractory MM
Autologous SCT safe and effective in older MM patients
Daratumumab in previously-treated AL amyloidosis
Daratumumab plus bortezomib/melphalan/prednisone in elderly,
transplant-ineligible, newly diagnosed MM
Adding busulfan to melphalan in high-risk MM
Effect of daratumumab on normal plasma cells, Igs and vaccine responses in pre-treated MM
Maintenance ± consolidation in newly diagnosed, transplant-eligible MM
Adding elotuzumab to pomalidomide/dexamethasone for relapsed/refractory MM
Please login below to download this issue (PDF)